Johnson & Johnson will restart shipments of its Covid-19 vaccine to Europe after the continent’s health agency concluded the benefits outweighed the risks even after it identified a “possible link” between the jab and rare blood clots.
嬌生公司(Johnson & Johnson)將重啓向歐洲交付其新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗，先前歐洲衛生機構得出結論稱，即便確認該疫苗與罕見的血栓之間「可能存在關聯」，接種該疫苗的益處仍大過風險。
您已閱讀7%（352字），剩餘93%（4393字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。